About the ReSPECT™ Clinical Trials
Plus Therapeutics is a U.S. pharmaceutical company developing innovative, targeted radiotherapeutics for adult & pediatric patients with rare & difficult-to-treat cancers. In the ongoing and planned ReSPECT™ Clinical Trials, the safety & effectiveness of an investigational therapy, Rhenium (186Re) Obisbemeda, will be evaluated in patients with central nervous system (CNS) tumors.
Recurrent
Glioblastoma
Leptomeningeal
Metastases
Pediatric
Brain Cancer
What Treatment is Being Studied in ReSPECT™?
The therapy is called Rhenium (186Re) Obisbemeda, administered to the patient as a single dose in either an inpatient or outpatient setting, depending on the tumor type.
What is Rhenium (186Re) Obisbemeda?
Rhenium (186Re) Obisbemeda is an innovative, targeted radiotherapeutic for central nervous system (CNS) tumors.
It is designed and intended to deliver a high, precise dose of radiation directly to specific cancer cells while sparing normal, healthy cells.
Where to Go for More Information?
Your healthcare provider will determine if you are eligible to participate in a ReSPECT™ Clinical Trial.
They can also answer your questions about your specific type of cancer and other treatment options.